60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
60 Degrees Pharmaceuticals received a recommendation from the independent Data Safety Monitoring Board to continue the Phase 2 B-Free study of tafenoquine for chronic babesiosis. The review of safety data from the first six patients through Day 30 found no issues requiring study modification. The study aims to enroll up to 100 patients to evaluate fatigue resolution over a 90-day ARAKODA regimen. Babesiosis is an orphan tick-borne disease with rising incidence and currently no FDA-approved treatments.
Key figures
- Drug Name
- ARAKODA (tafenoquine)
- Phase Of Trial
- Phase 2
- Enrollment goal
- 100
- Patients reviewed
- 6
- Drug half life days
- 16
- Annual incidence cases
- 25000
- Treatment duration days
- 90
- Confirmed infection goal
- 16
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.